PRKG1 and cystic fibrosis: To determine if iPSC HIOs have the potential to identify companion therapies for CF, we assessed the effects of known modulators of PKA and PKG phosphorylation since the phosphorylation of CFTR by PKA and PKG kinases have been implicated in regulating modulator efficacy (Figure 4e) [25,26].